Stephanie E. Gruner, RN
Ponatinib (Iclusig) induced a complete remission (CR) in one pediatric/adolescent patient with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), and demonstrated promising clinical activity in another, according to results from a case study presented at the 2018 American Society of Pediatric Hematology/Oncology (ASPHO) Conference.1
“It’s important to make it [clear] to clinicians that, when you do have a relapse or you’re seeing the BCR-ABL PCR is rising, consider mutational testing to identify these mutations and whether it’s clinically relevant to continue these drugs,” she said.
- Gruner SE, Sayeed H, Suarez-Ferguson L, et al. Ponatinib use in pediatric/adolescent and young adult patients with relapsed Ph+ ALL: a case series and review of the literature. Presented at: the 2018 ASPHO Conference; May 2-5, 2018; Pittsburgh, PA. Poster 079.
- Iclusic [package insert]. Cambridge, MA: ARIAD Pharmaceuticals Inc; 2017.
... to read the full story